Medicines and Driving Personalized Medicine and Medical Liability

  • Rossella Snenghi
  • Alessandro Amagliani


Physicians establish which medicines should be administered for the benefit of patients. The system of categorization for medicines and driving developed by the International Council on Alcohol, Drugs and Traffic Safety (ICADTS) and research groups within the European project DRUID (Driving Under the Influence of Drugs, alcohol and medicines) would allow the prescribing doctor to look for safer alternatives within a specific therapeutic class. A prime and exemplificative medico-legal case of driving under the influence of psychotropic medications is presented, analyzing the responsibilities of each participant: the patient, the general and specialized physician, and the driving licensing authorities. It is necessary to establish guidelines relating to the prescription of psychoactive medications, to be shared and adopted by all of the parties involved. The point of reference is that of Personalized Medicine, a paradigm which also entails the personalization of therapy, including a careful evaluation of the social sphere and impact on the community.


  1. 1.
    Hetland A, Carr DB (2014) Medications and impaired driving. Ann Pharmacother 48:494–506. doi: 10.1177/1060028014520882CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Dewar RE, Olson PL (2007) Human factors in traffic safety, 2nd edn. Lawyers & Judges Pub Co, Tucson, AZGoogle Scholar
  3. 3.
    Orriols L, Salmi LR, Philip P, Moore N, Delorme B, Castot A, Lagarde E (2009) The impact of medicinal drugs on traffic safety: a systematic review of epidemiological studies. Pharmacoepidemiol Drug Saf 18:647–658. doi: 10.1002/pds.1763CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Ogden EJ, Moskowitz H (2004) Effects of alcohol and other drugs on driver performance. Traffic Inj Prev 5:185–198. doi: 10.1080/15389580490465201CrossRefPubMedGoogle Scholar
  5. 5.
    Ojaniemi KK, Lintonen TP, Impinen AO, Lillsunde PM, Ostamo AI (2009) Trends in driving under the influence of drugs: a register-based study of DUID suspects during 1977–2007. Accid Anal Prev 41:191–196. doi: 10.1016/j.aap.2008.10.011CrossRefPubMedGoogle Scholar
  6. 6.
    Engeland A, Skurtveit S, Morland J (2007) Risk of road traffic accidents associated with the prescription of drugs: a registry-based cohort study. Ann Epidemiol 17:597–602. doi: 10.1016/j.annepidem.2007.03.009CrossRefPubMedGoogle Scholar
  7. 7.
    Verster JC, Mets MA (2009) Psychoactive medication and traffic safety. Int J Environ Res Public Health 6:1041–1054. doi: 10.3390/ijerph6031041CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Grime J, Blenkinsopp A, Raynor DK, Pollock K, Knapp P (2007) The role and value of written information for patients about individual medicines: a systematic review. Health Expect 10:286–298. doi: 10.1111/j.1369-7625.2007.00454.xCrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Janssen NB, Oort FJ, Fockens P, Willems DL, de Haes HC, Smets EM (2009) Under what conditions do patients want to be informed about their risk of a complication? A vignette study. J Med Ethics 35:276–282. doi: 10.1136/jme.2008.025031CrossRefPubMedGoogle Scholar
  10. 10.
    Monteiro SP, van Dijk L, Verstraete AG, Alvarez FJ, Heissing M, de Gier JJ (2012) Predictors for patient knowledge and reported behaviour regarding driving under the influence of medicines: a multi-country survey. BMC Public Health 12:59. doi: 10.1186/1471-2458-12-59CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Moller HJ, World Federation of Societies of Biological Psychiatry. Task Force on Unipolar Depressive D (2013) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry 14:334–85. doi: 10.3109/15622975.2013.804195
  12. 12.
    Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ, World Federation of Societies Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive D (2002) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3:5–43CrossRefGoogle Scholar
  13. 13.
    Nemeroff CB (2007) Prevalence and management of treatment-resistant depression. J Clin Psychiatry 68(Suppl 8):17–25PubMedGoogle Scholar
  14. 14.
    Murru A, Popovic D, Pacchiarotti I, Hidalgo D, Leon-Caballero J, Vieta E (2015) Management of adverse effects of mood stabilizers. Curr Psychiatry Rep 17:603. doi: 10.1007/s11920-015-0603-zCrossRefPubMedGoogle Scholar
  15. 15.
    Ramaekers JG (2003) Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. J Clin Psychiatry 64:20–29CrossRefPubMedGoogle Scholar
  16. 16.
    Verrotti A, Manco R, Matricardi S, Franzoni E, Chiarelli F (2007) Antiepileptic drugs and visual function. Pediatr Neurol 36:353–360. doi: 10.1016/j.pediatrneurol.2007.03.001CrossRefPubMedGoogle Scholar
  17. 17.
    Boyle J, Wolford D, Gargano C, McCrea J, Cummings C, Cerchio K, Lines C (2009) Next-day residual effects of gaboxadol and flurazepam administered at bedtime: a randomized double-blind study in healthy elderly subjects. Hum Psychopharmacol 24:61–71. doi: 10.1002/hup.986CrossRefPubMedGoogle Scholar
  18. 18.
    Dassanayake T, Michie P, Carter G, Jones A (2011) Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence. Drug Saf 34:125–156. doi: 10.2165/11539050-000000000-00000CrossRefPubMedGoogle Scholar
  19. 19.
    El-Saifi N, Moyle W, Jones C, Tuffaha H (2016) Quetiapine safety in older adults: a systematic literature review. J Clin Pharm Ther 41:7–18. doi: 10.1111/jcpt.12357CrossRefPubMedGoogle Scholar
  20. 20.
    Ravera S, Monteiro SP, de Gier JJ, van der Linden T, Gomez-Talegon T, Alvarez FJ, Partners DPW (2012) A European approach to categorizing medicines for fitness to drive: outcomes of the DRUID project. Br J Clin Pharmacol 74:920–931. doi: 10.1111/j.1365-2125.2012.04279.xCrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Nickel WR (1996) Medical screening and medical-psychological assessment as prerequisites for regranting of licenses: summary of recommendations. Alcohol Alcohol 31:605–607CrossRefPubMedGoogle Scholar
  22. 22.
    Ferrara SD, Snenghi R, Boscolo M (2006) Idoneità alla Guida & Sostanze Psicoattive. Linee Guida Metodologico-Accertative e Criteriologico-Valutative – Società Italiana Medicina Legale e delle Assicurazioni (SIMLA). Piccin Editore PadovaGoogle Scholar
  23. 23.
    Snenghi R, Forza G, Favretto D, Sartore D, Rodinis S, Terranova C, Nalesso A, Montisci M, Ferrara SD (2015) Underlying substance abuse problems in drunk drivers. Traffic Inj Prev 16:435–439. doi: 10.1080/15389588.2014.968656CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Department of Legal and Occupational Medicine, Toxicology and Public HealthUniversity-Hospital of PadovaPaduaItaly

Personalised recommendations